Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026

Data ReadoutpositiveEDG-7500Positive

AI Analysis

Summary

Edgewise Therapeutics announced positive top-line data from the Phase 2 CIRRUS-HCM trial of EDG-7500 in hypertrophic cardiomyopathy, to be presented as a late-breaking science presentation at the ESC Congress 2026.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

positive top-line data from 12-week Phase 2 CIRRUS-HCM trial

Importance:7/10

Sentiment:

0.80

Phase 2 datapositive trial resultslate-breaking presentationcardiologyHCM

Related Companies

$EWTX

Read the original article

Published by PR Newswire Biotech on August 24, 2026 12:00 PM

Read Original